CD8A and neoplasm: In the FUBP3(+) GBM group, the expression could enhance the antigen presentation of CD68+ macrophages through specific molecular pathways (chemokine receptor binding and the FC receptor signaling pathway), stimulating the immune effects of CD4+ and CD8+ T cells to enhance the killing effect on tumor cells.